Mesenchymal stromal cell delivery via an ex vivo bioreactor preclinical test system attenuates clot formation for intravascular application

Mesenchymal stromal cell delivery via an ex vivo bioreactor preclinical test system attenuates clot formation for intravascular application

Abstract While mesenchymal stromal cells are an appealing therapeutic option for a range of clinical applications, their potential to induce clotting when used systemically remains a safety concern, particularly in hypercoagulable conditions, such as in patients with severe COVID‐19, trauma, or canc...

Full description

Bibliographic Details
Main Authors: Brian O'Rourke, Sunny Nguyen, Arno W. Tilles, James A. Bynum, Andrew P. Cap, Biju Parekkadan, Rita N. Barcia
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:Stem Cells Translational Medicine
Subjects:
bioreactor
clot formation time
clotting
COVID‐19
ex vivo
heparin
Online Access:https://doi.org/10.1002/sctm.20-0454

Internet

https://doi.org/10.1002/sctm.20-0454

Similar Items